BROUNSTEIN RICHARD D
Known title: CHIEF FINANCIAL OFFICERCIK: 0001189694
BROUNSTEIN RICHARD D's purchase track record
BROUNSTEIN RICHARD D has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/21/2021 | BEAT | $17K | -46.9% | -60.8% | -19.0% |
| 11/11/2021 | BEAT | $30K | -58.9% | -70.6% | -15.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| BEAT | ▲ Buy | Option Exercise | 184 | $0 | 2/10/2023 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 760 | $0 | 12/2/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 759 | $0 | 11/2/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 760 | $0 | 10/2/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 757 | $0 | 9/2/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 757 | $0 | 8/1/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 757 | $984 | 7/5/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 757 | $0 | 6/2/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 757 | $0 | 5/2/2022 | View on chart |
| BEAT | ▲ Buy | Grant | 757 | $0 | 4/4/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 757 | $0 | 3/2/2022 | View on chart |
| BEAT | ▲ Buy | Grant | 757 | $0 | 2/2/2022 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 1,514 | $0 | 1/2/2022 | View on chart |
| BEAT | ▲ Buy | Open Market | 5,000 | $17K | 12/21/2021 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 19,465 | $82K | 11/11/2021 | View on chart |
| BEAT | ▲ Buy | Option Exercise | 9,732 | $41K | 11/11/2021 | View on chart |
| BEAT | ▲ Buy | Open Market | 5,000 | $30K | 11/11/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test
HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.
HeartBeam Receives FDA Breakthrough Designation for Heart Attack Test. HeartBeam Inc. announced that its Home Heart Attack Test system has been granted FDA Breakthrough Device designation. The designation recognizes the product’s potential to improve early detection of heart attacks at home. The company’s technology could expand its market presence and support future regulatory approvals. The news adds to the company’s positive momentum amid a mixed market session.